May 10, 2023 7:25am
Investors crave share pricing explanations because they give us an illusion of portfolio control. I know what a company is supposed to look like, be like, and smell like to succeed; bottom line, investors own the right to exit or enter sector’s share pricing - UNITE.
Earnings: Vericel (VCEL), BioLife Solutions (BLFS) and Precigen (PGEN)
April consumer prices increased 4.9% from a year ago, that was less than the 5% annual increase expected by economist.
Pre-open indications: 2 Negative indications
My interpretation of the morning’s numbers is written to be informative; it’s built on what happened or will happen behind the headline today, not tomorrow or yesterday.
Subscription is coming, it’s not conscription but, an offer to join our collective of like-minded investors! Join me … in the NO spin zone.
8:00 a.m. edition
Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session. My interpretation of the morning’s numbers is written to be informative; it’s built on what will happen behind the headlines today, not tomorrow or yesterday
Dow futures are UP +0.26% or (+89 points), S&P futures are UP +0.37% or (+15 point) and NASDAQ futures are UP +0.50% or (+68 points) early in the pre-open – post inflation report
Stock futures fell slightly Wednesday bracing for a key inflation report,
European markets were down,
Asia-Pacific markets fell.
Henry’omics:
We need to more than consider the economic environment - rising rates and inflation to comprehend the micro re “our” universe of cell and gene therapy companies …
Another busy earnings day.
Tuesday indexes closed lower, with the Dow diving -0.17% or -56.88 points, the S&P 500 fell -0.46% or -18.95 points and the Nasdaq plunged -0.06% or -77.36 points.
Economic Data Docket: April’s consumer price index report
· Analysts are calling for a 0.4% month-over-month increase in inflation and 5% rise from a year ago.
Tuesday’s (5/9) … RegMed Investors’ (RMi) closing bell: “the roller-coaster sector closes positive supplied by earnings releases, electronic trading and algorithmic “rules”. However, there is also STILL many a concern with sentiment and conviction in the cell and gene therapy sector.” … https://www.regmedinvestors.com/articles/12951
Ebb and flow:
Q2/23 – May – 2 negative and 5 positive closes
· April ended - 1 holiday, 8 positive close and 11 negative closes
Q1/23 –
· March – ended with 10 positive and 13 negative closes
· February – 1 holiday, 2 vacation, 7 negative and 8 positive closes
· January – 2 holidays, 11 positive and 9 negative closes
Companies in my headlights – It’s your decision; I provide ideas and context: INDICATIONS
Negative Indications:
Tuesday’s closing price, aftermarket dollar ($) and cent ($0.00) value and percentage (%)
bluebird bio (BLUE) closed up +$0.55 with a negative -$0.23 or -4.69% pre-open indication.
Intellia Therapeutics (NTLA) closed up +$0.79 with a negative -0.01 or -0.02% pre-open indication.
The BOTTOM LINE: I try to keep it simple and short!
I follow the dictum, quoting Churchill that “short words are best, and the old words when short are best of all.”
As I stated, I wouldn’t buy into ANY rally during earnings reporting season, I’d be selling and I have been RIGHT.
This week’s special, sector earnings continue rolling out … just one (1) NET INCOME to date yet, 21 net losses.
The cell and gene therapy sector could experience the “flight of Icarus” … since “our” universe have oscillated between gains and losses since the first of 2023!
Reiterating, “More frequently right than consequentially wrong … “The rubber is hitting the road, so those companies have to do quite well to justify it.” What is the “it” – as LPS (loss-per-share) numbers facilitate downslides.”
Investors should STILL be hesitant to add to positions re concerns of electronic trading i.e., algorithms seem to be the only ones leading any upside – go with flow.
I also hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!
At ANY time, this week, be ready to take partial profits and exit losers.
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
All investments are subject to risks. Investors should consider investment objectives.
Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions securities referred to in this publication.
